ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a leader in longevity telehealth solutions, announced the results of its 12-month, Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) clinical trial, the largest and longest decentralized, crowd-funded trial of its kind on Rapamycin safety for healthy aging in a normative aging population. The double-blind, randomized, placebo-controlled trial is also the first nationwide decentralized trial and the first large-scale intervention trial focused on healthy longevity outcomes.
Rapamycin, a promising gerotherapeutic that targets the biological aging process, has shown potential in preclinical studies to extend healthspan and prevent age-related diseases. However, until now, it has not been rigorously tested in generally healthy adults. The PEARL trial is the first to assess Rapamycin's effects in a real-world context, using a decentralized approach to include participants outside traditional clinical settings—mirroring how many already use the drug off-label. The study not only provides indications that intermittent, low-dose Rapamycin is safe for healthy adults, but also revealed measurable improvements in key markers of biological aging. These findings suggest that Rapamycin could play a critical role in preventive medicine, offering the general population an evidence-based strategy to potentially optimize health, extend years of vitality, and prevent the onset of age-related decline.
"Rapamycin has been shown to extend the life in every organism that it has been studied, making it the most promising therapy to help improve healthspan and lifespan,” said Dr. Sajad Zalzala, Co-Founder and Chief Medical Officer of AgelessRx. “The PEARL trial is a major step forward in our understanding of longevity science. With Rapamycin showing promising potential in extending healthspan, the PEARL trial was instrumental in translating research into real-world applications through the AgelessRx telehealth platform. We expect the PEARL trial will act as a catalyst to trigger larger and longer trials to accelerate the progress towards halting the effects of premature aging."
To date, the trial revealed some notable key findings. Specifically, the study provides evidence that low doses of Rapamycin had particularly pronounced effects in women, who typically face accelerated age-related decline. Beyond improving body composition metrics like muscle mass, Rapamycin use was also associated with higher quality of life metrics for study participants, specifically for reduced pain – key factors closely tied to mental and emotional well-being. These findings highlight Rapamycin’s potential to not only slow biological aging, but potentially improve both physical health and quality of life, both of which were particularly pronounced in female study participants.
AgelessRx's mission is to bring evidence-based longevity therapies and accessible preventative care to eligible adults seeking to optimize their healthspan and longevity. This trial aims to drive the longevity field forward by emphasizing greater scientific rigor and better-informed personalized care when it comes to new and emerging longevity treatments.
This study is a continuation of AgelessRx’s research initiatives, which are used to inform future clinical studies, patient offerings, and expert recommendations. The preprint of the study is now available here and is currently under consideration for peer-reviewed publication.
For additional information about the PEARL trial and AgelessRx’s clinical research, please visit agelessrx.com
About AgelessRx
AgelessRx, a comprehensive telemedicine platform at the forefront of the longevity revolution, is in pursuit of a future where extended lifespan and enhanced healthspan is a reality for everyone. Focused on customer satisfaction and affordability, AgelessRx transforms digital healthcare services, providing greater access to science-backed preventive treatments, tailored health plans, and longevity-guided care. For more information, visit agelessrx.com.
